Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?
about
Big Data Analytics for Prostate RadiotherapyRationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?Stereotactic body radiotherapy for organ-confined prostate cancer.Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamicsPhase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancerThe effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer.Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer.Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: a 5-year follow-up of an investigational study.Review of hypofractionated radiotherapy for prostate cancerRectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.Stereotactic body radiation therapy for prostate cancer.What do we know about the α/β for prostate cancer?Hypofractionated radiotherapy in prostate cancer.From radiobiology to technology: what is changing in radiotherapy for prostate cancer.Stereotactic body radiotherapy for primary prostate cancer: a systematic review.Hypofractionated radiotherapy for prostate cancer.Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trialSBRT and extreme hypofractionation: A new era in prostate cancer treatments?HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer.Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.Radiosensitivity and capacity for radiation-induced sublethal damage repair of canine transitional cell carcinoma (TCC) cell lines.Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro.Hypofractionation for prostate cancer.Will intrafraction repair have negative consequences on extreme hypofractionation in prostate radiation therapy?Stereotactic body radiation therapy for the primary treatment of localized prostate cancer.Comparison of IPSA and HIPO inverse planning optimization algorithms for prostate HDR brachytherapy.Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: a radiobiological modeling study.Radiobiological comparison of two radiotherapy treatment techniques for high-risk prostate cancer.Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.Treatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon.Impact of variable RBE on proton fractionation.Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients.Simultaneous integrated boost plan comparison of volumetric-modulated arc therapy and sliding window intensity-modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer.Optimal fractionation in radiotherapy with multiple normal tissues.The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.Reducing errors in prostate tracking with an improved fiducial implantation protocol for CyberKnife based stereotactic body radiotherapy (SBRT).Image-guided radiotherapy for prostate cancerDecreasing the Dose to the Rectal Wall by Using a Rectal Retractor during Radiotherapy of Prostate Cancer: A Comparative Treatment Planning Study
P2860
Q26744485-F4B7DBE2-B7FE-4E41-B7DF-AF193E8DF443Q26774847-FB530C60-A2B9-4811-B767-71E95CD4A245Q33528163-51B09868-3B1F-46C5-A7FF-53BA03EFFBA8Q34004539-646856CF-4CF2-4B2F-9B19-AC01402B40F5Q35111775-6E1CA116-AADC-44AC-B8E0-B18CE2E66B2EQ35166901-0A99A898-68E6-4D1A-9B45-B172DB05E7A5Q35530488-91668886-1EA4-4CD4-BEC2-0B128CD6653DQ35947797-37E85ABA-BE78-4E5B-B20B-444E0DF28391Q36154146-BBD3F867-3CA8-4730-8190-29D73C7A13D6Q36183668-111200C3-0A2A-4A31-A4F0-539BC69E9C21Q37725623-EDFA97F2-4FBE-468F-A7F8-87770012CE79Q37932543-A406B8C6-2A7F-457C-9C32-473E9B1DCE77Q38023478-5AE5050F-6351-4634-BFD0-3C900B6A925FQ38030596-1431B786-C3D4-4DF4-AC74-465CEF1A1C08Q38191990-A7B8D863-E5E8-4813-A6C0-DE30A168B186Q38243077-0FD0693C-C7C3-4098-A2F7-DC2ECF7270A9Q38283897-E2C25DA5-F001-4320-B6C8-7756A82F2A6AQ38611189-4B06070D-4B0D-4214-8BD7-4E3DB84F5811Q38677018-34F3B2CB-A0C1-4EE9-A628-EEEA93FC967BQ39234863-F7754D93-68AE-489A-AF52-3CF055E98C92Q39340402-63976147-0F14-4069-BBD0-35FACED37780Q39489159-F39B7C11-832A-41EB-B2BD-DEF68F501C0EQ39909671-9C672306-2517-46B8-9052-A01EA7ED3B64Q40004846-B76CD14A-B2BC-497D-B177-911A7375D481Q40452434-2D722CAC-99E2-4CF1-BC7C-1A6B3198F8B6Q41259152-B58209B2-CD2D-4DEA-95BD-75DD3E56DA63Q41706903-7586EDE3-B6F7-4D08-8B42-F0F1FBEFC633Q41775778-36931418-21B1-4D47-90B3-44DB59260B17Q41887636-C8D70D82-2ED2-4D16-9EAF-5976CA7A4E77Q42128313-32BBF960-AC1A-4D2B-AD95-BD11B7606C68Q42672870-1897F1C8-C994-436A-9946-197F9B750130Q42941156-E3B88E45-C90F-4B37-8E44-93922689D2DAQ44076578-4F6788E5-C570-427C-8F02-84DCF6185AE9Q45182086-58CED873-932F-4A82-8A32-E6594D459A22Q45342738-7E8005C7-7B52-411C-A213-EE728830433AQ50912967-05FB59D9-E88B-49E5-89FA-3C570234AAFCQ55033689-D6127A38-0E0F-40A6-9A3C-FFB9073E3F57Q55501070-985C5C84-7779-4F3C-9CFF-AE046C422572Q57112512-0E1A2423-E3F2-4801-8326-AFD7D529F9C5Q59050740-7F93DAB6-11AD-422F-8E3B-D96FDF402FF5
P2860
Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Is the alpha/beta value for pr ...... afely used in clinical trials?
@en
type
label
Is the alpha/beta value for pr ...... afely used in clinical trials?
@en
prefLabel
Is the alpha/beta value for pr ...... afely used in clinical trials?
@en
P1433
P1476
Is the alpha/beta value for pr ...... afely used in clinical trials?
@en
P2093
P304
P356
10.1016/J.CLON.2007.02.007
P577
2007-03-09T00:00:00Z